International Psoriasis Council

Advancing Knowledge. Improving Care.

María Julia

Cura

,

MD

Dermatologist
Hospital Italiano de Buenos Aires
Buenos Aires
,
Argentina
2024 Fellow
IPC Jr. Councilor
Dra. María Julia Cura is a co-leader of the psoriasis team at the Department of Dermatology, Hospital Italiano, Buenos Aires, Argentina. She is a dermatology professor at the National University of the Center (UNICEN) and is actively involved in teaching activities for dermatology residents and peers. She is a member of the Argentine Society of Dermatology (SAD) and the Argentine Society of Psoriasis (SOARPSO).

Dra. Cura has been engaged in clinical research since her residency and is completing a master’s in clinical research. She has presented at numerous national and international congresses and has published her research in peer-reviewed journals. She also participates in Project ECHOⓇ Psoriasis Argentina, a tele-mentoring initiative to empower dermatologists and expand access to best practices in psoriasis care. Dra. Cura has also contributed to developing a virtual community for psoriasis patients and has participated in podcasts focused on the disease. She has received multiple grants and scholarships, including the Strauss & Katz 2019 Scholarship to attend the American Academy of Dermatology (AAD) Annual Meeting, the 6th Congress of the Skin Inflammation & Psoriasis International Network (SPIN), the XXXV and XXXVI Annual Meetings of Latin American Dermatologists (RADLA), the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting and Trainee Symposium 2020, and the Imrich Sarkany Scholarship to attend the 2025 EADV Congress. She was also awarded the “Young Dermatologist Award 2018” by the Argentine Society of Dermatology.

In 2024, Dr. Cura was selected as an IPC International Fellow and completed her fellowship under the mentorship of IPC Councilor Professor Diamant Thaçi at the University of Lübeck, Germany.
Last Updated:
06/30/2025

Areas of Interest

Switching and dose reduction of biologics and small molecules; Dengue in psoriasis

IPC Committees / Groups

Latin America Working Group

Languages Spoken

English, Spanish

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026